Login / Signup

Efficacy of HE4, CA125, Risk of Malignancy Index and Risk of Ovarian Malignancy Index to Detect Ovarian Cancer in Women with Presumed Benign Ovarian Tumours: A Prospective, Multicentre Trial.

Vincent DochezMélanie RandetCéline RenaudeauJérôme DimetAurélie Le ThuautNorbert WinerThibault ThubertEdouard VaucelHélène CaillonGuillaume Ducarme
Published in: Journal of clinical medicine (2019)
The combination of HE4 and CA125 represents the best tool to predict the risk of ovarian cancer in patients with a PBOT.
Keyphrases
  • study protocol
  • clinical trial
  • protein kinase
  • phase iii
  • phase ii
  • randomized controlled trial
  • cross sectional
  • double blind